Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels

Adam J. Walker, Sandy A. Burnett, Kyoko Hasebe, Jane A. McGillivray, Laura J. Gray, Sean L. McGee, Ken Walder, Michael Berk, Susannah J. Tye

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Several animal models are currently utilised in the investigation of major depressive disorder; however, each is validated by its response to antidepressant pharmacotherapy. Few animal models consider the notion of antidepressant treatment resistance. Chronic daily administration of adrenocorticotropic hormone (ACTH) or corticosterone can alter behavioural responses to antidepressants, effectively blocking antidepressant efficacy. Herein, we demonstrate that ACTH-(1-24) (100μg/day; 14 days) blocks the immobility-reducing 'antidepressant' effects of a single dose of imipramine (10. mg/kg) in the forced swim test. This finding was accompanied by altered monoamine tissue levels in the prefrontal cortex (PFC) 1. h after exposure to the acute stress of the forced swim test. PFC tissue from ACTH pre-treated animals contained significantly higher serotonin, noradrenaline and adrenaline concentrations relative to saline pre-treated controls. Conversely, dopamine levels were significantly decreased. Altered plasma corticosterone responses to ACTH injections were observed over the treatment course. Measures were taken on treatment days 1, 4, 8, 11, 14 and 15. ACTH administration initially enhanced plasma corticosterone levels, however, these normalised to levels consistent with control animals by day 14. No differences in corticosterone levels were observed across the treatment time course in saline-treated animals. Taken together these results indicate that pre-treatment with ACTH (100μg/day; 14 days) blocks the antidepressant effects of imipramine (10. mg/kg), significantly alters key PFC monoamine responses to stress and downregulates glucocorticoid responses. These results suggest that chronic ACTH treatment is a promising paradigm for elucidation of mechanisms mediating antidepressant treatment resistance.

Original languageEnglish (US)
Pages (from-to)76-83
Number of pages8
JournalBehavioural Brain Research
Volume242
Issue number1
DOIs
StatePublished - Apr 1 2013

Keywords

  • ACTH
  • Adrenocorticotrophic hormone
  • Animal model
  • Corticosterone
  • FST
  • HPA
  • Monoamine
  • OFT
  • PFC
  • TRD
  • Treatment resistant depression

ASJC Scopus subject areas

  • Behavioral Neuroscience

Fingerprint Dive into the research topics of 'Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels'. Together they form a unique fingerprint.

  • Cite this

    Walker, A. J., Burnett, S. A., Hasebe, K., McGillivray, J. A., Gray, L. J., McGee, S. L., Walder, K., Berk, M., & Tye, S. J. (2013). Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behavioural Brain Research, 242(1), 76-83. https://doi.org/10.1016/j.bbr.2012.12.033